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Abstract
A trans-National Institutes of Health initiative, Nutrition and Dietary Supplement Interventions for
Inborn Errors of Metabolism (NDSI-IEM), was launched in 2010 to identify gaps in knowledge
regarding the safety and utility of nutritional interventions for the management of inborn errors of
metabolism (IEM) that need to be filled with evidence-based research. IEM include inherited
biochemical disorders in which specific enzyme defects interfere with the normal metabolism of
exogenous (dietary) or endogenous protein, carbohydrate, or fat. For some of these IEM, effective
management depends primarily on nutritional interventions. Further research is needed to
demonstrate the impact of nutritional interventions on individual health outcomes and on the
psychosocial issues identified by patients and their families. A series of meetings and discussions
were convened to explore the current United States’ funding and regulatory infrastructure and the
challenges to the conduct of research for nutritional interventions for the management of IEM.
Although the research and regulatory infrastructure are well-established, a collaborative pathway
that includes the professional and advocacy rare disease community and federal regulatory and
research agencies will be needed to overcome current barriers.
Keywords
Inborn errors of metabolism; Newborn screening; Genetic; Rare diseases; Dietary supplements;
Medical foods
1. Introduction
The purpose of this paper is to describe the need for research on nutritional interventions
used in the management of individuals with inborn errors of metabolism (IEM) across their
life span. To facilitate research in this arena, the trans-National Institutes of Health (NIH)
initiative, Nutrition and Dietary Supplement Interventions for Inborn Errors of Metabolism
(NDSI-IEM), was launched in 2010 and an NIH-sponsored NDSI-IEM workshop was held
in December 2011 to initiate discussions with the IEM community. The findings from the
NDSI-IEM workshop, input from additional rare disease and metabolic disorders experts,
and a review of the literature were used in the development of this paper. A description of
IEM, the research and regulatory infrastructure in the United States that governs the
discovery and approval of pharmaceutical drug treatments and nutritional interventions for
rare disorders and IEM, the challenges and barriers to conducting research and developing
new treatments and interventions and proposed solutions to these challenges, and tools and
resources useful for researchers are provided.
1.1. NDSI-IEM: an initiative to build a research framework for IEM
NDSI-IEM was established within NIH’s Office of Dietary Supplements (ODS) and Office
of Rare Diseases Research (ORDR). The mission of NDSI-IEM is to: identify gaps in
research on the safety and utility of nutritional interventions for IEM. Through collaboration
with multiple interested parties, challenges and barriers that limit evidence-based research
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and solutions to improve the evidence base for the nutritional interventions used in IEM will
be identified.
The NDSI-IEM workshop that was convened in late 2011 included representatives from
advocacy and patient organizations; professional associations; companies that make
prescription drugs, medical foods, and other nutritional products used in IEM; the Health
Resources and Services Administration’s (HRSA) Genetic and Newborn Screening Services
Regional Collaboratives; agencies, institutes, and centers within the Department of Health
and Human Services; and the metabolic clinical, research, and academic community. In
addition to identifying knowledge gaps and the challenges and barriers to the conduct of
evidence-based research for nutritional interventions for IEM, activities were proposed that
would support the metabolic research community. These activities have been organized into
short-, mid-, and long-range projects and in addition to the development of this paper, other
NIH-sponsored and professional association activities are underway.
1.2. IEM: the need for a research agenda
IEM include inherited biochemical disorders in which specific enzyme defects interfere with
the normal metabolism of exogenous (dietary) or endogenous protein, carbohydrate, or fat
[1]. As a result of reduced or absent enzyme activity, there is an accumulation of a precursor
to the controlled reaction and a subsequent deficiency of a product which can lead to
morbidity and mortality. This definition is the intellectual basis for understanding the use of
dietary manipulation to manage these disorders. Nutritional interventions can bypass or
overcome the metabolic consequences of the genetic mutations for some IEM, but are
required lifelong [1]. Nutritional products used in the dietary management of IEM include:
medical foods that provide the majority of nutrient needs, specialized for individual
disorders; and dietary supplements that are used to enhance diminished catalytic function,
replace conditionally essential nutrients, or provide essential nutrients that may be missing
due to dietary restrictions. The regulation of these products is described in Sections 2.1 and
2.3.
Phenylketonuria (PKU), the “poster child” for much of our understanding of IEM,
exemplifies successful management by dietary manipulation and its impact on the patient,
family, and society. PKU is due to a defect in the functioning of phenylalanine hydroxylase
(PAH) or secondarily to defects in synthesis or recycling of tetrahydrobiopterin, a cofactor
for PAH. PAH is an enzyme that converts the amino acid phenylalanine (PHE) into its sister
amino acid, tyrosine. Left untreated, PKU causes PHE to accumulate in the blood and brain
and can lead to severe cognitive impairment in virtually all individuals affected. A series of
studies in affected patients and their newborn siblings demonstrated that restricting PHE in
the diet by lowering protein intake and supplementing the other 19 amino acids in a special
formula prevented progression of the condition. The success of dietary intervention led to
the development of newborn screening for PKU in all countries of the developed world and
the potential to eliminate severe cognitive impairment due to this condition. While costly,
the diet proved to be an excellent investment for society showing a favorable benefit-to-cost
ratio [2,3]. The development and use of multiplex technologies such as tandem mass
spectrometry has expanded the number of disorders screened and most State newborn
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screening programs are now screening newborns for more than 30 conditions [4,5].
Newborn screening also has improved our understanding of the clinical variability and
heterogeneity of IEM and has identified patients whose biochemical changes may have
otherwise gone unnoticed in the absence of the screening process.
The dramatic success of nutritional interventions for PKU and some other IEM comes at a
price to the patient who faces foregoing a normal diet, and the emotional and financial cost
to the patient and family who must commit to this difficult dietary regimen for life. An
increasing market for nutritional products for the management of IEM detected through
expanded newborn screening, and vastly improved medical foods and development of foods
modified to be low in protein have helped to alleviate the severity and monotony of the
dietary restrictions endured by patients with these disorders. However, the improved
nutritional composition and palatability of new products have not totally mitigated the
difficulties in coping with current dietary regimens. In addition, as many patients eventually
relax their dietary vigilance, a new set of medical and psychological problems develops
[6,7].
While nutritional interventions are the standard-of-care for many IEM, the extent to which
all patients identified through newborn screening or in a clinical setting will benefit from or
even require such interventions, is unknown. In addition, patients and their families and
health care professionals may need to rely on nutritional interventions that often have not
been studied in clinical trials. Participants of the 2011 NDSI-IEM workshop indicated that
further research is needed regarding the impact of nutritional interventions on health
outcomes and on the psychosocial issues identified by patients and their families. To
understand the complexities involved in conducting research on nutritional interventions for
IEM, we provide an overview of the entities that fund research and regulate medical
products below.
2. Current federal research infrastructure for rare disorders and IEM
2.1. The Orphan Drug Act and IEM
The Orphan Drug Act (ODA) [8,9], was approved by the 98th U.S. Congress in 1983, and
subsequently amended in 1984, 1985, and 1988. ODA facilitates the development and
availability of drugs to treat rare diseases and provides the legislative basis for most of the
research for rare disorders, including IEM. Because of ODA, both NIH and the Food and
Drug Administration (FDA) now have specific programs that focus on research and
development of treatments for IEM, as outlined below. While the legislation connects the
research activities of NIH with the regulatory processes of FDA for drug development for
rare disorders, including IEM, there is no similar connection between the research and
regulatory processes for nutritional interventions for IEM.
The 1988 amendment defined a rare disease as a disease or condition with prevalence of less
than 200,000 individuals in the U.S. population and for which there is little realistic chance
of generating industry interest in drug development because the cost of development would
far outweigh any revenue generated by sales. Rare diseases, representing an estimated 7000
discrete disorders [10], collectively affect six percent of the U.S. population or between 25
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and 30 million people [11]. The term “orphan product” was defined by the ODA to describe
drugs, biologics, and medical devices developed to treat rare diseases, including IEM.
The 1988 amendment to ODA also created a definition of medical foods [12], as: “a food
which is formulated to be consumed or administered enterally under the supervision of a
physician and which is intended for the specific dietary management of a disease or
condition for which distinctive nutritional requirements, based on recognized scientific
principles, are established by medical evaluation.” Medical foods include infant formulas
developed specifically for IEM and those products developed and marketed to persons over
1 year of age that meet the definition of a medical food. Regulatory infrastructure for
approval for the use of drugs for rare disorders, including IEM, is quite different from the
regulatory infrastructure that governs the marketing, distribution, and third-party
reimbursement for dietary supplements and medical foods. As a result, a dichotomy exists
between the federal regulatory, research, and payer agencies and the pharmaceutical industry
and research communities regarding the use of drug treatments versus dietary supplements
and medical foods in the management of IEM.
2.2. National Institutes of Health
2.2.1. Research programs and initiatives—NIH is the largest funder of biomedical
research in the world. Research at NIH is conducted through its intramural programs at its
main campus and through extramural research programs based at academic institutions
throughout the U.S. The NIH Clinical Center, which opened in 1953, together with
academic health centers, including those with a Clinical and Translational Science Award
(CTSA) [13], remains the principal venues for rare disease research in the United States.
Over the past two decades, provisions in ODA and the launching of several other new
offices, programs, and intra- and extramural initiatives at NIH have stimulated research to
discover the causes and develop treatments for rare diseases, including IEM. NIH tools and
resources useful for researchers are listed in Table 1.
ORDR was created in 1993 within the Office of the Director of NIH to address the need for
rare disease research. Subsequently, Public Law 107–280, the Rare Diseases Act of 2002
[14], established ORDR by statute. In 2003, ORDR, in collaboration with six NIH Institutes
and Centers created and funded the Rare Diseases Clinical Research Network (RDCRN) to
facilitate multisite collaborative clinical research in rare disorders, including IEM, and to
train young physician-researchers. RDCRN currently consists of 17 consortia, each of which
is focused on a minimum of three related rare disorders and partners with patient advocacy
groups [15]. The goals of each consortium are to identify biomarkers for disease risk,
severity, and progression; develop clinical outcome measures; and encourage the
development of new approaches to diagnosis, prevention, and treatment. Three RDCRN
consortia are relevant to IEM: the Urea Cycle Disorders Consortium; the North American
Mitochondrial Disease Consortium; and the Sterol and Isoprenoid Research Consortium
[15].
The Eunice Kennedy Shriver National Institute of Child Health and Human Development’s
(NICHD) Newborn Screening Translational Research Network (NBSTRN) [16] also
supports IEM research. The NBSTRN’s purpose is to provide infrastructure support to
Camp et al. Page 5






















investigators to advance diagnostics and treatment of disorders detected through newborn
screening programs and conditions that may be amenable to newborn screening in the
future. Resources developed include: a virtual repository of de-identified residual dried
bloodspots for use by investigators; laboratory testing algorithms and decision matrices; and
a longitudinal pediatric data repository to allow long-term clinical follow-up and research of
infants detected with IEM or other congenital abnormalities.
2.3. Food and Drug Administration
The mission of FDA is to promote and protect the public health by assuring the safety,
efficacy, and security of human and veterinary drugs, biologics, medical devices, the
nation’s food supply, cosmetics, and products that emit radiation. FDA recognizes that
streamlining the process for drug and biological product development is critical for
development of products used to treat IEM and other rare and common disorders [17].
FDA has several programs that coordinate and oversee products for rare diseases, including
IEM. Within the Center for Drug Evaluation and Research (CDER), the Rare Diseases
Program (RDP) was created in 2010 to facilitate and support the research, development,
regulation, and approval of drugs and biological products for the treatment of rare disorders.
RDP serves as the focal point of CDER to the rare disease drug development community.
RDP coordinates the development of CDER policy, procedures, and training for the review
and approval of treatments for rare diseases. Additionally, RDP actively collaborates with
external and internal rare disease stakeholders to support the development of treatments for
rare disorders. For example, RDP meets regularly with NIH’s ORDR and Therapeutics for
Rare and Neglected Diseases Program.
FDA’s Office of Orphan Product Development (OOPD) is also involved in advancing
development of products (drugs, biologics, devices, and medical foods) that demonstrate
promise for the diagnosis, management, and/or treatment of rare diseases or conditions.
OOPD administers the Orphan Drug Designation, the Humanitarian Use Device, and the
Orphan Products Grants programs.
Recently, FDA created the Rare Diseases Council with representatives from across several
FDA Centers including the Office of the Commissioner, the Center for Biologics Evaluation
and Research, CDER, the Center for Devices and Radiological Health, and the Center for
Food Safety and Nutrition. The goal of this Council is to coordinate development of
products for rare disorders across FDA. Under the Food and Drug Safety and Innovation Act
passed by Congress in 2012 [18], there are provisions that allow sponsors to request that
their drug be designated as a “breakthrough therapy” and outlines procedures for an
expedited FDA review and approval process.
2.3.1. Development, regulations, and definitions for drugs, dietary
supplements, and medical foods used in IEM—Under the Federal Food, Drug, and
Cosmetic Act (FD&C Act), FDA has defined a drug as a substance recognized by an official
pharmacopoeia or formulary that is intended for the diagnosis, cure, mitigation, treatment, or
prevention of disease. In order for drugs and biological products to be approved in the U.S.,
there must be substantial evidence of effectiveness. Evidence generally consists of adequate
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and well-controlled investigations so that the effect of the drug can be distinguished from
the effect of other influences such as spontaneous change in the course of the disease,
placebo effect, or biased observation. This evidentiary standard must be met for products
used to treat rare diseases as well [19]. However, FDA has regulatory flexibility in
interpreting the requirements for demonstration of substantial evidence of effectiveness for
rare disease products. For example, carglumic acid for the treatment of N-acetylglutamate
synthase, or NAGS, deficiency was approved by FDA in 2010 based on a case series derived
from fewer than 20 patients and comparison to a historical control group.
A dietary supplement is defined as a product taken by mouth that contains a “dietary
ingredient” (e.g., a vitamin, mineral, botanical, and amino acid) intended to supplement the
diet [20]. Dietary supplements must meet the requirements of the Dietary Supplement
Health and Education Act (DSHEA) [20], which is governed under the FD&C Act [21]. In
general, the FDA regulations for dietary supplements are different from those for
prescription or over-the-counter drugs. Unlike drugs, dietary supplements do not require
premarket review or approval by the FDA. While the dietary supplement manufacturer is
responsible for having evidence that their products are safe and the label claims are truthful
and not misleading, they do not have to provide that evidence to FDA before the product is
marketed [22]. However, dietary supplements may not be promoted as a treatment,
prevention, or cure for a specific disease or condition. If a dietary supplement were used to
treat, prevent, or cure disease, it would be considered a drug. As such, the dietary
supplement would be regulated under drug statutes and require well-controlled trials to
establish evidence of safety and effectiveness to support the intended claim.
With regard to medical foods, there are no requirements for FDA approval of medical foods
prior to marketing and medical foods do not need to be registered with FDA. However, the
manufacturers of medical foods must be registered with and are inspected by FDA, as is the
case for all food manufacturers in the U.S. and they must meet the requirements of good
manufacturing practices. Medical foods for persons over 1 year of age are exempt from the
nutrition labeling, health claims, and nutrient content claim requirements of the Nutrition
Labeling and Education Act of 1990 [23]. All manufacturers of infant formulas must notify
FDA at least 90 days prior to marketing a new infant formula or an infant formula with a
major change. An infant formula that is represented and labeled for use by an infant who has
an IEM is exempted from certain requirements. However, if a manufacturer wants to market
this type of infant formula, a submission must be made that includes a detailed description
of the medical condition for which the infant formula is represented and includes
justification for any deviations from any of the nutrient requirements (see: 21 CFR 107.50c
[21]).
2.3.2. The status of drug development for rare disorders and IEM—Total
spending on all health-related research has tripled since the ODA and successive legislation
were enacted [24,25]. Despite a historical dearth of therapeutics for rare diseases, product
development for these disorders appears to be increasing. Since the passage of the ODA in
1983, more than 400 drugs and biological products have been approved to treat rare diseases
[26] compared to the 10 products approved to treat rare diseases between 1973 and 1983. In
a recent review of rare disease product approvals in the U.S. between 2006 and 2010, new
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molecular entities and new biologics for rare diseases comprised 30% of all marketing
applications reviewed and approved by FDA during the study period. Notably, more than
half of the 26 new biologic applications submitted to CDER were for rare disease
indications. Furthermore, approval rates for marketing applications for rare and common
disease indications were similar (77% approval rate for rare disease products and 71%
approval for non-rare disease products) [27–29]. For IEM, there were six products approved
during this same time period (2006–2010). Two of these products, Kuvan® (sapropterin
dihydrochloride) for PKU, and Carbaglu® (carglumic acid) for NAGS deficiency, are used
in IEM that prior to the development of the drugs, relied primarily on nutritional
interventions. The other four products were developed for Pompe disease, Hunter syndrome,
and Gaucher, in which nutritional interventions are not used as part of their standard
management.
Kuvan® was the first FDA-approved drug therapy for PKU. Kuvan® is used in conjunction
with a low-PHE diet, reducing blood PHE levels in some patients. The introduction of
Kuvan® as an adjunct therapy required specific dietary protocols to be developed by genetic
metabolic dietitians in partnership with medical geneticists and the drug manufacturer.
Pharmacologic agents for PKU and other IEM are currently being developed. For example,
for PKU, pegylated phenylalanine ammonia lyase (PEG-PAL), will enter Phase 3 clinical
trials in 2013 [30]. PEG-PAL is administered by injection and appears to be effective in
lowering blood PHE levels, even in patients on a completely unrestricted diet. Clinical trials
have focused on use in adolescent and adult patients with poorly controlled blood PHE
levels.
3. IEM research partners
3.1. Pharmaceutical and medical food industry
Members of the pharmaceutical, dietary supplement, and medical food industry are in an
important position to increase availability of the products that support the nutritional
management of IEM. Before these products can come to market, research and development
require time, money, and for some products, successful approval through FDA regulatory
processes mandated by Congress. The industry has engaged genetic metabolic professionals
to assess the needs of the IEM community and has provided unrestricted research and
educational grants to allow research and other projects to move forward. The industry also
has been able to facilitate and support the development of multicenter clinical trials and
patient registries.
3.2. Genetic professionals
Health care professionals, inclusive of medical biochemical geneticists, genetic metabolic
dietitians, and genetic counselors, who manage the treatment of individuals with IEM, are
often located in large academic centers and engage in clinical, translational, and basic
science research. These health care professionals focus on the diagnosis, treatment, and
long-term follow-up of patients with IEM. Medical biochemical geneticists have specific
subspecialty training in the care of patients with IEM. They are responsible for the overall
coordination of patient care and directly manage medical issues related to IEM in both the
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outpatient and inpatient setting. In institutions where a medical biochemical geneticist is not
available, a medical geneticist often assumes these responsibilities. A metabolic genetic
counselor assists in the assessment of an IEM, acts as an advocate for the patient through the
process of the metabolic genetics evaluation, and helps him/her understand what a diagnosis
of an IEM means for each family member. Genetic metabolic dietitians design and
implement nutritional interventions aimed at mitigating the biochemical abnormality
presented by the IEM and ensure that the individual maintains an appropriate nutritional
status. Standards of professional practice for genetic metabolic dietitians were published in
2008 [31] and their role as advanced practitioners in genetics has been characterized [32].
Together these health care professionals provide complex care to patients with IEM and are
central to the development of a research infrastructure as they have direct access to patients
and know the research questions that need to be addressed.
3.3. Primary care and public health professionals
Primary care professionals, including pediatricians, internists, family physicians,
obstetricians, and nurse practitioners, have a role in the care of individuals with IEM. These
roles span evaluation and referral, co-management with the public health newborn screening
system and genetic health care professionals. The patient-centered medical home (PCMH)
model of primary care, which emphasizes continuous, comprehensive, and coordinated care,
provides a mechanism to gather patient data over the life span of a patient and a system of
co-management with other health care professionals. While about half of the states are
implementing PCMH for their Medicaid populations [33], the Patient Protection and
Affordable Care Act (ACA) of 2010 will encourage expansion of PCMH through incentives
and resources [34]. Natural history studies and the development of treatments require a
system of long-term follow-up (LTFU) for those affected by IEM. Since many individuals
with IEM are first identified within newborn screening programs, public health professionals
play an essential role in maintaining the system of LTFU for these children. Together,
through systems of PCMH and LTFU, primary care and public health professionals will be
critical to successful research endeavors for IEM.
3.4. Patients, families, and disease-specific advocacy groups
Patients with IEM, their families, and patient support and advocacy groups are essential
partners in any research endeavor. Their concerns include the cost and palatability of
products used in disease management, the variation in treatment protocols from clinic to
clinic, and the variable access to product coverage mechanisms from state to state. Patients
and their families, and advocacy groups are often able to educate Congress about needed
legislation and research through their own personalized stories.
3.5. International metabolic community
Collaboration with the international metabolic community will strengthen research
endeavors in IEM by providing investigator expertise and increasing the number of patients
available for research. The NDSI-IEM workshop included metabolic specialists from
Australia, France, Switzerland, and United Kingdom. Workshop participants voiced a need
to support international collaboration to define diseases, develop standards of care, and
compare definitions of medical foods globally. Several international initiatives in rare
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diseases and IEM specifically serve as examples of these collaborations and include the
Global Rare Diseases Patient Registry and Data Repository (GRDR) in ORDR and the
International Rare Diseases Research Consortium [35].
4. Establishing a coordinated infrastructure for collaboration
For institutional transformation to occur and collaboration to be established, partnering
entities need to work together by sharing resources, information, materials, and personnel.
Collaborators then bring work, money, knowledge and/or experience to the task of
developing partnerships and infrastructure to develop treatments for rare disorders. The
identified tasks then are “outsourced” to the defined group of collaborators. The gaps in the
translational pathway are bridged through these partnerships to distribute the risks and
benefits involved in research and development for rare disorders [36].
Collaborative approaches to the rapeutics development are becoming more important for
rare diseases and IEM, especially when no approved therapy is available. The work done in
eosinophilic esophagitis [37] and the RDCRN’S Urea Cycle Disorders Consortium serve as
examples of the benefits of collaboration across multiple sectors and with multiple partners.
In particular, the Urea Cycle Disorders Consortium enabled the development of a treatment,
Raviciti (glycerol phenylbutyrate), for the chronic management of some urea cycle disorders
in patients ages 2 years and older. It is intended for patients whose urea cycle disorder
cannot be managed by a protein-restricted diet or amino acid supplements alone. Along with
the consortium, NIH’s National Center for Advancing Translational Sciences (NCATS) and
NICHD and the National Urea Cycle Disorders Foundation were collaborators in this study.
NDSI-IEM workshop participants emphasized the need to utilize the existing RDCRN and
NBSTRN infrastructure and to build upon them for future research. Through NBSTRN and
RDCRN, collaborations have been formed for research, to provide clinical care, and to
gather a significant number of individuals and families with rare disorders to conduct
research. While these collaborations offer access to large-scale resources such as biobanks
or data warehouses, they also increase the complexity of coordination, accountability,
management, and communication between the researcher and participant. An additional
challenge in multicenter approaches is providing clinical services for patients from out of
state. A State’s Medicaid program generally does not contract with health care professionals
practicing in a second State to provide care for another State’s population unless that health
care professional is also licensed in that first state. These challenges are beginning to be
mitigated through several efforts, as exemplified by the HRSA-funded Regional Genetics
and Newborn Screening Collaboratives [38] These Collaboratives have developed several
regional models to deliver subspecialty care across state borders while allowing families to
remain primarily with their local provider for their clinical care. The NBSTRN was able to
utilize the Region IV Regional Genetics and Newborn Screening Collaborative’s multi-site
service infrastructure to support a collaborative research effort, while preserving the
patient’s medical home.
Improved means of capturing patients eligible for research and clinical trials in a distributed
way with a common protocol can also be seen as a health information exchange (HIE) issue
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rather than a logistics issue of sending patients to distant centers. Information that captures
the key elements of each individual patient and links them to a larger set of data provides the
necessary foundation for assessing the optimal health outcome of individuals with IEM.
Since research funds generally do not pay for the care of patients locally, an informatics
approach, combined with telemedicine would allow for broad multi-state collaboration,
balancing the need for local care and payer access with national research. The partnership
between some of the HRSA-funded Regional Genetics and Newborn Screening
Collaboratives [38] and the NIH-funded NBSTRN described above is an example of using
HIE.
5. Conducting research in IEM
In rare disease research, randomized controlled trials that are adequately powered to
demonstrate effectiveness often are considered difficult. Reasons include small sample size,
heterogeneity and geographic diversity in phenotype, and affected individuals’ exposure to
many prior treatments or interventions. Additionally, meaningful health outcomes over the
clinical course of a disorder may not be measurable for many years. Constructing a well-
designed clinical evaluation is possible, however, and challenges can be overcome through
the use of specialized study designs and biostatistical techniques that maximize data from
small numbers of subjects [39].
5.1. Research study designs
5.1.1. Natural history studies—The foundation of successful pharmaceutical drug
treatment or dietary management of IEM rests upon an understanding of the disease
pathophysiology, the mechanism of action of the candidate therapeutic, the expected effect
of the intervention on the disease, and how the effect will be measured. Data collected from
a well-designed natural history study may provide important information to enable
appropriate design of clinical trials or alternative designs (e.g., appropriate patient
population, length of study, and selection of clinically meaningful end-points). Several of
the current NBSTRN projects are examples of natural history studies for IEM, for example
the Longitudinal Pediatric Data Resource [16].
5.1.2. Comparative Effectiveness Research (CER) and patient-centered
outcomes—To receive full approval for commercial marketing in the US, all FDA-
approved drugs must demonstrate substantial evidence of clinical effectiveness and safety,
and must be shown to have a favorable benefit-to-risk assessment in the treatment of the
disease [40]. CER allows stakeholders, including affected individuals, policymakers, and
health care providers, to compare explicitly the potential benefits and harms of different
treatment approaches.
Most CER on rare diseases, including IEM, requires collaboration across multiple sites to
obtain a sufficient patient population for a study. The NBSTRN and RDCRN are two
programs that provide the collaborative infrastructure necessary to conduct CER for IEM,
while addressing the need for a patient-centered approach.
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The critical need to include patient perspectives on therapeutic effectiveness of treatments is
underscored by the creation of the non-governmental Patient-Centered Outcomes Research
Institute (PCORI) by the ACA Patient-centered outcomes research is designed to help
people, together with their families, researchers, and health care providers, better assess
treatment options. A patient-centered approach not only captures what is essential to patients
and families, it potentially engages lay advocacy groups in the design of studies, facilitating
compliance with treatments and wider participation in the studies.
5.1.3. Alternate designs—Alternate approaches to study designs include [39,41]: case-
control studies, crossover studies, quasi-experimental design studies, and “before-and-after
studies” designs (a form of time-series design, commonly used retrospectively but can also
be done prospectively). Griggs et al. [39] describe multiple approaches for study designs that
could be used for rare disorders.
Many of the existing databases and registries established by the NBSTRN and RDRCN (see
Section 5.4) offer the opportunity to construct a “simulated” or faux randomized control
trial. The existing collaborative multi-centered infrastructure provided by the NBSTRN and
the RDCRN capture the majority of the patients affected by various disorders into registries
or centralized databases. Utilization of common data elements in these programs also allows
researchers to begin to recognize patterns of clinical effects that may support decisions
concerning clinical validity and utility of various therapeutic approaches. Although the
research activities undertaken by the NBSTRN or the RDRCN have been focused largely on
natural history studies, this work is essential and provides the platform for the development
and assessment of both pharmaceutical drug treatments and nutritional interventions for
IEM.
5.2. Identifying endpoints and biomarkers for rare disease research
Identification of potential clinical outcome measures that will be used as endpoints should
be considered as early as possible and prior to initiating clinical trials. An appropriate
clinical endpoint must be based on a clearly defined disease process and detailed
understanding of how the endpoint is expected to change over time in a specific disease.
While the identification of a well-defined endpoint may be difficult to establish in rare
diseases, careful collection of natural history data for a disease should include information
that will aid in the identification of potential clinical endpoints for study.
Surrogate endpoints are measurements or a physical sign used as a substitute for a clinically
meaningful endpoint that would measure directly how a patient feels, functions, or survives.
FDA’s Accelerated Approval Regulations for reliance on a “surrogate endpoint that is
reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence,
to predict clinical benefit” [42] have been in place for many years. For example, everolimus
was approved in 2010 for the treatment of subependymal giant cell astrocytoma (SEGA)
associated with tuberous sclerosis which requires therapeutic intervention but is not a
candidate for curative surgical resection. The approval was based on an analysis of change
in SEGA volume. Since 2009, FDA has issued 21 approvals under accelerated approval
regulations. A detailed description of these regulations may be found elsewhere [43].
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Biomarkers are also potentially useful in clinical development programs for drugs and can
be used during all phases of drug development. Biomarkers can identify an appropriate
target population, establish or refine dosing of the product, and assess the effect of clinical
intervention on a disease (i.e., clinical endpoint). Careful consideration of potential
biomarkers and their role in clinical trials should be performed early and discussed with
FDA.
5.3. Recruitment and retention of research subjects
Beyond the basic problems common to all clinical trials, recruitment and retention of the
few geographically dispersed and often quite ill patients with rare disorders are major
challenges for IEM investigators. Patients and families may not have the resources to travel
to academic research centers and conversely, not all academic health centers will have the
required expertise for all rare disorders. Thus, creative mechanisms must be developed and
implemented to maximize recruitment and retention of research subjects.
5.4. Patient registries, databases, and common data elements for rare disorders
Patient registries and collective databases provide mechanisms to overcome geographic
dispersion while furnishing a collective infrastructure to assemble sufficient numbers of
patients and a means for tracking and retaining patients enrolled in specific protocols for
robust research. Through utilization of these data collection tools, regular, lifelong contact
with patients can be maintained. These tools and ongoing contact with the patient and family
also provide mechanisms for locating patients who are lost-to-follow-up. Patients and
families may report health status to the participating research and clinical centers and
protocol-specific outcome data may be collected. The registries additionally provide a
mechanism to collect cumulative therapeutic exposure data (via therapeutic summaries
completed online by treating institutions) on patients completing active therapy.
Many current registries and databases were built on different platforms using different
terminology and vocabulary, thus making it extremely difficult to share data or information
among them. Because the rarity of the disorders necessitates a multi-centered approach, it is
critical that data definitions and study protocols be standardized to ensure data compatibility
among those participating. To address some of these issues, two projects within NIH have
been launched: the Global Rare Disease Patient Registry and Data Repository (GRDR)
project in ORDR and the NBSTRN natural history study project in NICHD. Both initiatives
have worked together with the NIH National Library of Medicine and the HRSA funded
Regional Genetics and Newborn Screening Collaboratives to develop common data
elements to facilitate data sharing and data aggregation. The GRDR utilizes rare disease
patient registries to create a registry with aggregated and de-identified patient information.
The NBSTRN utilizes a network of databases to support the capture and storage of
longitudinal clinical data from individuals following newborn screening. The registries and
databases allow analyses within a disease or across many diseases.
5.5. Institutional review boards: a multicenter approach
Although a system of networks may address limited specialty resources and bring
geographically disparate patients together, differing consent and institutional review board
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(IRB) procedures required by individual centers may impede multicenter trials. There have
been numerous efforts to reform the IRB review process for multicenter studies [44–47].
Marsolo [48] reviews two approaches—centralized and federated IRBs. Centralized IRBs
are not tied to an institution, may be disease or geographical location specific, and may be
established commercially or by networks of researchers [48]. Concerns related to research
integrity and lack of local context in centralized IRBs led to the development of federated
IRBs. Federated IRBs allow institutions to select the degree of control they wish to retain in
the IRB process, ranging from using their own IRB to selecting the IRB of record. For
example, about half of NICHD-funded National Children’s Study sites use the IRB of the
NICHD as the IRB of record [49]. A toolkit with materials and information about
establishing a Federated IRB model for multi-site collaborations is available upon request
from the National Children’s Study at: ContactNCS@mail.nih.gov.
5.6. The genetic workforce
The current medical genetic service workforce is not expected to meet patient care needs in
the next 5–15 years, widening the gap between the expansion of knowledge, service needs,
and workforce size [50]. Young physicians are not entering the fields of either genetics/
genomics in general or IEM, specifically [51]. Many states and geographic areas have an
inadequate supply of medical geneticists while the need has increased due to the ongoing
expansion of newborn screening for congenital disorders.
Few analyses exist that set the baseline for how many such providers are needed.
Assessments by the Royal College of Physicians in 2004 indicate that the health care system
requires one clinical geneticist and associated service team per 250,000 people [52]. The
medical genetics workforce in the U.S. numbers about 1132 or 1 per 616,200 persons [53],
suggesting that there are insufficient medical geneticists to meet the growing need for
genetic services.
Genetic counselors and genetic metabolic dietitians (who are registered dietitians with
specialized expertise in the nutritional management of IEM) work with patients with
complex genetic disorders, including inborn errors of metabolism. To date, there have been
no published surveys to evaluate the number of genetic counselors or registered dietitians
with specific expertise in IEM.
5.6.1. The need for increased training and research opportunities—Health care
professionals have many demands on their time, even beyond patient care, which limits their
ability to devote significant time to research. Most are academically based and spend about
45% of their time in direct patient care with the balance applied to teaching, research, and
administration. While serving a prominent role in patient care, only four percent of
registered dietitians overall hold doctoral degrees [54] limiting their ability to serve
independently as principal investigators.
Strategies to increase the genetic metabolic professional workforce and their research
expertise will be critical to effective development of a research infrastructure. There are a
number of initiatives in progress by the American Society of Human Genetics, the American
College of Medical Genetics and Genomics and the National Society of Genetic Counselors
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to expand the entire genetic services workforce, including activities that target high school,
college, medical school, and residency training. Additionally, a recommendation from the
NDSI-IEM workshop focused on providing research training opportunities for the genetic
metabolic workforce. To this end, a series of webinars and educational sessions at
professional meetings are planned.
There are also specific initiatives that focus on the need for increased genetics education and
training of primary care professionals. The Genetics in Primary Care Institute (GPCI) was
established as a cooperative agreement between HRSA’s Maternal & Child Health Bureau
and the American Academy of Pediatrics to address this need [55]. In the context of a
medical home, the GPCI will foster genetic literacy and the integration of genetic medicine
into health information technology. As the capacity to engage in multi-directional HIE and
genetic literacy improves and increases, the role of primary care providers as research
partners should increase.
6. Need for novel approaches for IEM product development
6.1. Strategy for product development
The research plan for product development is linked to study design and therefore should
begin well before clinical trials are contemplated. The overall strategy requires collaboration
across multiple sites to achieve a sufficient patient population to study and benefits from
careful advanced planning and interaction with FDA. All interested parties and should be
identified to participate in the planning process and potential sources of support also
identified. Important considerations during the planning process include: definition of the
disease, the populations to be studied, the overall goals of the intervention, and the
sequential steps that will need to be taken to achieve the overall goals. Additional critical
elements include review of the currently available knowledge about the intervention and the
disease; how effects of the intervention will be measured; and whether currently existing
measurement tools are adequate for assessment of these effects.
Currently, a non-iterative process prevails in the development of pharmaceutical drug
treatments, medical foods, and dietary supplements for IEM. Study designs often do not
provide a coordinated approach that couples development of an intervention and criteria for
regulatory approval for use in a clinical setting with an ongoing accumulation and
examination of knowledge to refine the intervention. Research strategies should provide for
an iterative collection of data to periodically inform researchers, clinicians, and relevant
federal agencies about the clinical validity or utility of the intervention, allowing for
adjustments or refinements as needed.
It was noted at the NDSI-IEM workshop by some product developers that reimbursement
cannot be sought for clinical interventions under development. Further, it was also noted that
lack of insurance coverage may keep patients who might want to be in a clinical trial from
participating. One suggested solution by NDSI-IEM workshop participants is to allow for
reimbursement for a clinical intervention, while linking with the research and development
process through a coordinated effort among federal research funders, health care payers, and
regulatory agencies. What is unique to this approach is allowing for reimbursement for the
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intervention during the clinical trial period. It should be noted that as of January 1, 2014,
regulations under the ACA will require health insurance coverage for the routine medical
costs of people taking part in clinical trials. Insurers will not be allowed to drop or limit
coverage because a person chooses to participate in a clinical trial. This regulation will apply
to all clinical trials involving life-threatening diseases and would be applicable to many
IEM.
6.2. Regulatory science
Regulatory science is another very important but challenging area of research that impacts
the development and availability of treatments and interventions for diseases. Regulatory
science is a systemized body of knowledge (practiced by FDA and similar regulatory
agencies world-wide) concerning drug and other product regulations, regulatory standards,
law, and procedures across many disciplines with an aim to improve assessment of
experimental drug therapies, nutritional interventions, and diagnostics. It includes public
protection-oriented medical product regulations and scientific methods utilized in the
evaluation and approval of all the products that FDA regulates [56].
FDA has advanced a strategic plan for regulatory science [56] with the aim of delivering
efficacious medical products to patients by increasing efforts to reduce the uncertainties in
the FDA development and approval process. As previously outlined, under the current
regulatory and research infrastructure, there are significant differences between the
regulatory agencies and the pharmaceutical and research communities in the development
and approval of pharmaceutical drug treatments versus that of medical foods and dietary
supplements, in general and for IEM. Without FDA approval—and in the current regulatory
infrastructure medical foods and dietary supplements for management of IEM are not
approved by the FDA—there are potentially problematic shortfalls in knowledge about the
safety and utility of nutritional interventions, and in the ability of individuals with IEM to
obtain and receive coverage for these interventions. If the current regulatory infrastructure is
deemed to be restrictive in facilitating goals of approving new therapies, policies may be
needed to facilitate translational science and build models of approval for new drug
therapies and nutritional interventions that combine the assessment process with interim
approval and use of these therapies or interventions. In order to follow such a pathway,
developers of medical foods and dietary supplements for IEM may need to follow a
developmental and regulatory pathway similar to that required for pharmaceuticals used in
the management of IEM.
6.3. Federal coordination to enhance research
The December 2011 NDSI-IEM workshop participants pointed to a need for improved
coordination among the federal agencies, a sentiment also articulated by Health and Human
Services Secretary, Kathleen Sebelius in Health Affairs [57]. The participants highlighted
two primary areas for coordination: within the agencies’ solicitation processes and during
the process of product development.
NDSI-IEM workshop participants proposed that NIH and FDA proactively provide
researchers with guidance in the conduct of research and navigating the intricacies of the
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research and development pathway for treatments and interventions for IEM. For example,
receipt, review, and funding schedules for federal agencies vary considerably, presenting
applicants with a challenging planning task. NIH has standard due dates for most competing
applications which are fairly uniform across NIH Institutes and Centers [58]. However,
targeted solicitations such as a Request for Applications have their own special due dates
and separate funding schedules. Furthermore, other agencies (Centers for Disease Control
and Prevention, and HRSA) have separate review and funding schedules for their
competitions. Regulatory submissions processes (for agencies like the FDA) also have
distinct schedules and timelines. Applicants considering submissions to multiple agencies
within a short time frame, or with linked projects requiring coordinated planning, may need
to contact staff at multiple agencies for guidance on scheduling and other submission
requirements.
6.4. Applying new technologies
There is clear interest in applying new genomics concepts and technologies to newborn
screening and other aspects of child health. New technologies such as genomics and related
“omics” have the potential to identify new drug targets to pursue or to refine current
treatments, for example, by stratifying populations based on genetic-based biomarkers.
Genomic data would reveal how individuals might respond to, be resistant to, or have
adverse effects from a drug or nutritional interventions such as medical foods or dietary
supplements. NDSI-IEM workshop participants suggested that a centralized DNA-
sequencing facility to analyze newborn screening samples could study different IEM-
associated mutations, genotyping every infant who has a positive newborn screen. A similar
suggestion was proposed by participants in a workshop entitled ‘Newborn Screening in the
Genomic Era: Setting a Research Agenda’ sponsored by NICHD, the National Human
Genome Research Institute and ORDR that took place in December 2010 [59].
NDSI-IEM workshop participants pointed to the need to better understand the phenotype/
genotype relationships of the various IEM to improve drug treatments and nutritional
interventions through faster, cheaper molecular characterization. Our earliest understanding
of IEM as an “all or nothing condition” was quickly modified by the observation of inter-
and intra-familial variation in phenotypes, as the clinical course of IEM is variable. These
clinical variations are due not only to genetic or genomic variants but also to differences in
the patient’s natural environment and physiological responses to the biochemical disruption.
Many questions including those of predicting disease course or understanding outcomes
over time in patients with later onset conditions will require longitudinal data collection
from a patient rather than a point-in-time assessment. With large-scale data collection, more
bioinformatics capacity and capability will be necessary. To allow for assessment of
individual phenotypic data, they need to be stored in an accessible location at either remote
or distributed sites including within a patient’s own electronic medical record. Standard
descriptive terms will be necessary so that data entry and interpretation will be as uniform as
possible. Thus current efforts to develop common data elements will be critical moving
forward.
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The Mitochondria Phenome Knowledgebase (MitoPhenome) represents an early example of
a tool designed to aid clinicians and researchers in understanding how genetic variation
among individuals contributes to clinical disease phenotypes and traits [60]. Detailed
information on distinct clinical disease phenotypes of known mitochondrial gene defects
were catalogued into a searchable database after classification of each clinical or
biochemical feature using National Library of Medicine Medical Subject Headings (MeSH)
terms. As genomic and bio computational technologies continue to advance, our level of
understanding of phenotype/genotype relationships will rise significantly, which will have a
positive effect on treating IEM [59].
7. Conclusions: addressing the problem and achieving the goal
The lay and professional rare disease communities and federal research, funding, regulatory,
and payer agencies will need to collaborate to develop an improved roadmap to overcome
current barriers and address the challenges that impede conducting evidence-based research
for nutritional interventions for IEM. Below we propose action steps that, if implemented
broadly, could transform biomedical research and how federal support for and approval of
new nutritional interventions are obtained.
7.1. What is needed
1. Improve coordination among the regulatory agencies, industry and research
communities, through collaborations among federal agencies (those responsible for
regulation, research and health care payments), industry and nongovernmental
organizations.
2. Develop models of collaboration and co-management that facilitate necessary
partnerships between subspecialty and specialty providers.
3. Develop coordinated regional and federal infrastructures to:
• Utilize HIE to integrate the service delivery system with researchers.
• Enhance opportunities for collaboration while distributing cost sharing and
sharing of resources.
• Utilize a centralized or federated IRB approach.
4. Establish CER and patient-centered research models to:
• facilitate participation in research projects,
• facilitate participatory and shared decision-making processes, and
• increase understanding by advocacy groups of the importance of research.
5. Design research studies to:
• identify appropriate populations for study
• identify clinically meaningful endpoints and biomarkers/surrogate
endpoints in rare disorders
• establish patient-centered, rigorous approaches to study designs.
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6. Develop strategies to increase training opportunities for both specialty and
subspecialty providers in the area of metabolic and genetic/genomic disorders.
Individuals with IEM and their families face challenges daily. Thus, seizing the opportunity
for collaboration to mitigate these challenges and improve outcomes is critical. The
concerned entities involved in drug, biologics, medical food, and dietary supplement
development, including academia, industry, and federal funders and regulators must
continue to work collaboratively and proactively for the benefit of public health. Proactive
collaboration ultimately would entail the use of appropriately structured clinical trials for not
only the development of pharmaceuticals for the treatment of IEM but also medical foods
and dietary supplements used in the management of IEM. The goal of development and
facilitation of optimal management strategies for those individuals affected with rare and
orphan diseases is mutually important for all involved entities.
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Table 1
Examples of NIH tools and resources for researchers.
The NIH Guide for Grants and Contracts (http://grants.nih.gov/grants/guide) lists
NIH funding opportunities.
The NIH Research Portfolio Online Reporting Tools (RePORTER) database (http://projectreporter.nih.gov/reporter.cfm) provides information
on projects that NIH
currently funds or has funded in the past. RePORTER is helpful for establishing a research network and identifying research that NIH is already
funding.
Information about U.S. and international clinical trials is available from clinicaltrials.gov
website, though nutritional interventions not subject to FDA oversight, and therefore
may not be listed.
The NIH Clinical Center’s website (http://clinicalcenter.nih.gov) provides details
on ongoing NIH clinical trials. At this time, use of the Clinical Center is restricted
to intramural investigators and their collaborators. However NIH may open the
Clinical Center to extramural investigators in the future.
Common Fund Regulatory Science Program fosters development, availability and
evaluation of new or improved ways to understand and improve evaluation of
product safety, quality, effectiveness, and manufacturing throughout the life-cycle
of a product (http://commonfund.nih.gov).
Common Fund Undiagnosed Diseases Program was initiated to promote use of
genomic data in disease diagnosis and engage basic researchers to elucidate
the mechanisms underlying the diseases so that treatments may be identified
(http://commonfund.nih.gov/diseases/).
Therapeutics for Rare and Neglected Diseases program (http://www.ncats.nih.gov/research/rare-diseases/trnd/trnd.html) build collaborations
with NIH, FDA and
academic scientists, nonprofit organizations, and pharmaceutical and biotech-
nology companies to speed development of new therapies.
Cures Acceleration Network (http://www.ncats.nih.gov/funding-and-notices/can/can.html) was established to stimulate the development of high
need cures for
debilitating and life threatening diseases by reducing the number of barriers
that investigators face between the time of basic research discoveries and
initiation of clinical trials.
The Bridging Interventional Development Gaps program (http://www.ncats.nih.gov/research/rare-diseases/bridgs/bridgs.html) provides
successful applicants developing
therapeutic agents with access to critical resources in support of pre-clinical studies.
Discovering New Therapeutic Uses for Existing Molecules (http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/therapeutic-uses/
therapeutic-uses.html)
is a collaborative pilot program of NCATS designed to develop partnerships
between pharmaceutical companies and the biomedical research community
to advance therapeutic development.
Tissue Chip for Drug Screening initiative represents an interagency collaboration
with Defense Advanced Research Projects Agency (DARPA) and NCATS (http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/
therapeutic-uses/therapeutic-uses.html).
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